Has Ira Roth, MD received payments from drug or device companies?

Yes. Drug and device makers reported $161 in general payments to Ira Roth, MD across 7 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Ira Roth, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Ira Roth, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Ira Roth, MD

Cardiovascular Disease · New York, NYNPI 1588626451

Payments from drug & device makers

$161in general payments, 2019–2025

Across 7 payments — averaging $23.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

E.r. Squibb & Sons, L.L.C.$95
Amgen$44
Lilly USA, LLC$23

What the payments were for

Food & beverage$161100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
E.r. Squibb & Sons, L.L.C.	4	$95
Amgen	2	$44
Lilly USA, LLC	1	$23

How this compares

$161 in reported general payments places this provider in the 10th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York →

Medicare billing

Part B allowed, 2024

$319,290

Medicare patients

568

Services billed

3,034

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	160	$175,608
EntrestoSacubitril/Valsartan	27	$45,938
XareltoRivaroxaban	28	$39,881
Repatha SureclickEvolocumab	22	$24,642
JardianceEmpagliflozin	20	$19,300
FarxigaDapagliflozin Propanediol	12	$18,422
OzempicSemaglutide	12	$15,152
Atorvastatin Calcium	719	$6,694
Rosuvastatin Calcium	414	$5,529
Metoprolol Succinate	394	$5,261
Diltiazem 24hr Er (Cd)Diltiazem Hcl	46	$3,196
Ezetimibe	80	$2,518
Losartan Potassium	194	$2,270
Amlodipine Besylate	265	$1,824
Amlodipine-ValsartanAmlodipine Besylate/Valsartan	34	$1,543

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in New York

James MinNew York$41.1M
Robert RosensonNew York$6.9M
Roxana MehranNew York$6.4M
Roger HajjarNew York$5.2M
Philippe GenereuxNew York$4.4M
Gregg StoneNew York$3.7M
Valentin FusterNew York$2.9M
Tamim NazifNew York$2.2M
Howard WeintraubNew York$1.7M
Anuradha Lala-TrindadeNew York$1.5M

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →